Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer
Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer
About this item
Full title
Author / Creator
Publisher
New York: Springer US
Journal title
Language
English
Formats
Publication information
Publisher
New York: Springer US
Subjects
More information
Scope and Contents
Contents
Summary
Entrectinib is a pan-tyrosine-kinase inhibitor that targets oncogenic rearrangements in
NTRK
,
ROS1
and
ALK
. The combined results of two clinical trials demonstrated the efficacy of entrectinib in
ROS1
-rearranged NSCLC. Because the development of drug resistance is inevitable, it would be helpful to determine th...
Alternative Titles
Full title
Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7066105
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7066105
Other Identifiers
ISSN
0167-6997
E-ISSN
1573-0646
DOI
10.1007/s10637-019-00795-3
